Treatment of malignant glioma: A problem beyond the margins of resection

Journal of Cancer Research and Clinical Oncology, Supplement

Volumn 127, Issue 4, 2001, Pages 217-225

  Giese, A ^a   Westphal, M ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Chemotherapy; Experimental therapy; Glioma

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; CARBOPLATIN; CARMUSTINE; HYBRID PROTEIN; INTERLEUKIN 4; LOBRADIMIL; THYMIDINE KINASE; IMMUNOMODULATING AGENT; IODINE 125; IRIDIUM;

ARTICLE; BEAM THERAPY; CANCER CELL; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CAROTID ARTERY; CELL INVASION; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; GENE THERAPY; GLIOBLASTOMA; HUMAN; LEUKOENCEPHALOPATHY; LYMPHOKINE ACTIVATED KILLER CELL; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RECURRENT CANCER; TREATMENT FAILURE; TUMOR ASSOCIATED LEUKOCYTE; BRAIN TUMOR; CANCER GROWTH; CANCER STAGING; HERPES SIMPLEX VIRUS; HISTOPATHOLOGY; REVIEW; TUMOR RECURRENCE; VIRUS RECOMBINANT; GLIOMA; IMMUNOTHERAPY; PATHOLOGY;

GENE THERAPY; GLIOMA; HUMANS; IMMUNOTHERAPY; MAGNETIC RESONANCE IMAGING;

EID: 0034741232     PISSN: 09439382     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004320000188     Document Type: Article

References (63)

1. Dosimetry and dose-response relationship in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81c6 therapy
2. Early postoperative magnetic resonance imaging after resection of malignant glioma: Objective evaluation of residual tumor and its influence on regrowth and prognosis
3. Gene therapy for gliomas: Molecular targets, adenoviral vectors, and oncolytic adenoviruses
4. Effect of extent of surgical resection on survival and quality of life in patients with supratentorial glioblastoma and anaplastic astrocytomas
5. CT prognostic criteria of survival after malignant glioma surgery
6. Phase 1 studies of treatment of malignant gliomas and neoplastic meningitis with 131I radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Mel-14 F(ab)2 - A preliminary report
7. Biodegradable polymers for controlled delivery of chemotherapy with and without radiation therapy in the monkey brain
8. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas
9. Patient age, histologic features, and length of survival in patients with glioblastoma multiforme
10. Computerized tomographic and pathologic studies of the untreated, quiescent, and recurrent glioblastoma multiforme
11. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas
12. Aggressive surgery for malignant supratentorial gliomas
13. Survival after stereotactic biopsy of malignant gliomas
14. Interstitial irradiation of brain tumors, using a miniature radiosurgery device: Initial experience
15. Superselective application of cisplatinum in recurrent human glioblastoma
16. In vivo gene transfer with retroviral vector producer cells for treatment of experimental brain tumors
17. Surgery in the treatment of malignant glioma: Current status and future perspectives
18. Resection, biopsy, and survival in malignant glial neoplasms
19. Modulation of the immune response by transforming growth factor ß
20. Supratentorial malignant glioma: Patterns of recurrence and implications for external beam local treatment
21. Glioma invasion in the central nervous system
22. Determinants of human astrocytoma migration
23. Specific attachment and migration of human astrocytoma cells on human but not murine laminin
24. Migration of human glioma cells in response to tumor cyst fluids
25. Dichotomy of astrocytoma migration and proliferation
26. Thromboxane synthase regulates the migratory phenotype of human glioma cells
27. Phase II studies of RMP-7 and carboplatin in the treatment of recurrent high grade glioma
28. Multivariate analysis of factors affecting postoperative survival in malignant astrocytoma
29. Influence of type and extent of surgery on early results and survival time in glioblastoma multiforme
30. Complete regression of established human glioblastoma xenograft by interleukin-4 toxin therapy
31. Imaging-based stereotaxic serial biopsies in untreated glial neoplasms
32. Lymphokine-activated killer cells, interleukin-2 and tumor necrosis factor-a in malignant glioma: Clinical and laboratory findings
33. Gene therapy for brain tumors
34. The role of tumor resection in the treatment of glioblastoma multiforme in adults
35. Tumor regression with regional distribution of the targeted toxin TF-CRM 107 in patients with malignant brain tumors
36. Radiation therapy For neoplasms of the brain
37. Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion
38. Cytoskeleton-plasma membrane interactions
39. Interstitial brachytherapy for malignant brain tumors
40. Altered gene expression in human astrocytoma cells selected For migration: I, thromboxane synthase
41. The growth of glioblastoma multiforme in neurosurgical practice
42. Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins
43. Computerized tomography in the prognosis of malignant cerebral gliomas
44. The role of surgery in the management of supratentorial intermediate and high-grade astrocytoma in adults
45. Interstitial implant radiosurgery of brain tumors: Radiobiology, indications, and results
46. Integrin-ligand binding properties govern cell migration speed through cell-substratum adhesiveness
47. The relationship between survival and the extent of the resection in patients with supratentorial malignant gliomas
48. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells
49. Tumor-specific anti-epidermal growth facto receptor variant III monoclonal antibodies: Use of a tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts
50. Factors affecting the extension of peritumoral brain oedema. ACT study
51. Local application of radiola beled monoclonal antibodies in the treatment of high grade gliomas: A six-year clinical experience
52. Surgical decision making for malignant brain tumors
53. Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human glioma and their relation to angiogenesis
54. A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma
55. Isolation and characterization of human malignant glioma cells from histologically normal brain
56. Morbidity and survival after 1,3-bis(2-chloroethyl)-1-nitrosourea wafer implantation for recurrent glioblastoma: A retrospective case-matched cohort series
57. Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: A randomized double-blind study
58. The influence of the extent of surgery on the neurological function and survival in malignant glioma. A retrospective analysis in 243 patients
59. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas
60. Intratumoral infusion of the monoclonal antibody against the epidermal growth factor receptor in patients with advanced malignant glioma
61. Supratentorial anaplastic gliomas in adults
62. Current neurosurgical management and the impact of the extent of resection in the treatment of malignant gliomas of childhood: A report of the Childreńs Cancer Group Trial No.CCG-945
63. Integrin dependent activation of MAP kinase: A link to shape-dependent cell proliferation